Non-Small-Cell Lung Cancer — Expanded Access Programs

• Study on MK-1084 and Other Treatments for Non-Small Cell Lung Cancer — Merck Sharp & Dohme LLC
• Study on Intismeran (V940) With or Without Pembrolizumab for High-Risk Stage I Non-Small Cell Lung Cancer — Merck Sharp & Dohme LLC
• Study on Calderasib and Durvalumab for Treating Non-Small Cell Lung Cancer — Merck Sharp & Dohme LLC
• Study on Investigational Combination Therapy with BNT326 and BNT327 for Advanced Non-Small Cell Lung Cancer (NSCLC) — BioNTech SE
• First-in-Human Study of CKD-703 for Advanced Solid Tumors and Non-Small Cell Lung Cancer — Chong Kun Dang Pharmaceutical
• First Human Trial of BLU-924 for Advanced Cancers with KRAS Mutations — Blueprint Medicines Corporation
• Study on the Safety and Effectiveness of ENV-501 for Patients with HER3-Positive Solid Tumors — Endeavor Biomedicines, Inc.
• Study on VS-7375 for Patients with KRAS G12D-Mutated Solid Tumors — Verastem, Inc.
• Phase 2 Study on Immunotherapy for Non-Small Cell Lung Cancer Resistant to Previous Treatments — M.D. Anderson Cancer Center
• Phase 2 Study of Osimertinib and Selumetinib for Advanced EGFR Mutant Lung Cancer — Dana-Farber Cancer Institute
• Phase 2 Study of VS-7375 for Patients with KRAS G12D-Mutated Non-Small Cell Lung Cancer — Verastem, Inc.
• Phase 2 Study of Zanidatamab for Patients with HER2-positive Tumors — Jazz Pharmaceuticals
• Phase II Study of HLX43 for Advanced Non-Small Cell Lung Cancer (NSCLC) — Shanghai Henlius Biotech
• Phase III Study of Dato-DXd and Rilvegostomig for Stage I Adenocarcinoma NSCLC After Tumor Removal — AstraZeneca
• Study Comparing Savolitinib and Osimertinib with Savolitinib and Placebo in Patients with Advanced Lung Cancer — AstraZeneca
• Study on Combining Immunotherapy and Radiotherapy for Non-Small Cell Lung Cancer — University of Chicago
• Study Comparing Divarasib and Pembrolizumab with Standard Chemotherapy for Advanced KRAS G12C-Mutated Lung Cancer — Hoffmann-La Roche
• Study on the Safety and Effects of Divarasib with Other Cancer Treatments for Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation — Hoffmann-La Roche
• Study on Abemaciclib for Patients with Previously Treated KRAS Mutated Lung Cancer — Eli Lilly and Company
• Study on BIO 300 and Chest Radiation Therapy for People with Non-Small Cell Lung Cancer and Interstitial Lung Disease — Memorial Sloan Kettering Cancer Center
• Study on Cemiplimab with Chemotherapy and Other Treatments for Adults with Operable Non-Small Cell Lung Cancer — Regeneron Pharmaceuticals
• Study on Ivonescimab with Dato-DXd or Osimertinib for Non-Small Cell Lung Cancer — Memorial Sloan Kettering Cancer Center
• Study on Ivonescimab for Treating Non-Small Cell Lung Cancer — Memorial Sloan Kettering Cancer Center
• Study on Ivonescimab, Chemotherapy, and Stereotactic Radiosurgery for People with Non-Small Cell Lung Cancer — Memorial Sloan Kettering Cancer Center
• Study on Durvalumab and Chemotherapy Before and After Surgery for Treating Resectable Non-small Cell Lung Cancer — AstraZeneca
• Study on New Treatment Combinations for Non-Small Cell Lung Cancer (NSCLC) — AstraZeneca
• Study on Osimertinib With or Without Chemotherapy for First-Line Treatment in Patients with EGFR-Mutated Non-Small Cell Lung Cancer — AstraZeneca
• Study on Osimertinib With or Without Chemotherapy Compared to Chemotherapy Alone for Treating EGFRm Positive Non-Small Cell Lung Cancer Before Surgery — AstraZeneca
• Study on Pembrolizumab With or Without Chemotherapy and Additional Treatments for Advanced Non-Small Cell Lung Cancer — Merck Sharp & Dohme LLC
• Study on Tepotinib and Osimertinib for Treating MET Amplified Non-Small Cell Lung Cancer After Osimertinib Relapse — EMD Serono Research & Development Institute, Inc.
• Study on Trastuzumab Deruxtecan for People with Non-Small Cell Lung Cancer — Memorial Sloan Kettering Cancer Center
• Study on the Safety and Effects of Telisotuzumab Vedotin for Previously Treated Non-Squamous Non-Small Cell Lung Cancer — AbbVie
• Study on the Effectiveness of WSD0922-FU in Patients with Advanced Non-Small Cell Lung Cancer with C797S Mutation — Wayshine Biopharm, Inc.
• Study Comparing Chemotherapy Plus Osimertinib to Chemotherapy Plus Placebo in Patients with Non-Small Cell Lung Cancer (NSCLC) — AstraZeneca
• Study on the Safety and Effectiveness of A2B530 CAR T-Cell Therapy for Solid Tumors with CEA Expression and HLA-A*02 Loss — A2 Biotherapeutics Inc.
• Study on Two Dosing Methods of Nivolumab with Ipilimumab and Chemotherapy for Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer — Bristol-Myers Squibb
• Study on ANS02 for Patients with EGFR Mutation-Positive Non-Small Cell Lung Cancer — Avistone Biotechnology Co., Ltd.
• Study on the Safety of AZD6750 for Adults with Advanced or Metastatic Solid Tumors — AstraZeneca
• Study on PF-08634404 with Chemotherapy for Adults with Advanced or Metastatic Non-Small Cell Lung Cancer — Pfizer
• Expanded Access Program for Zipalertinib in Advanced Non-Small Cell Lung Cancer — Taiho Oncology, Inc.
• Study on Oral EGFR Inhibitor Sunvozertinib for Advanced Non-Small Cell Lung Cancer with EGFR or HER2 Mutation — Dizal Pharmaceuticals
• Study on Entrectinib for Treating Solid Tumors with Specific Gene Changes — Hoffmann-La Roche
• Study on Zongertinib for Treating Surgically Removed Non-Small Cell Lung Cancer with HER2 Mutations — Boehringer Ingelheim
• Study on CAN-2409 Plus Prodrug with Standard Immune Therapy for Advanced Lung Cancer — Candel Therapeutics, Inc.
• Study on Ivonescimab for Initial Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) with High PD-L1 Levels — Summit Therapeutics
• Study on Using a Blood Test to Predict Treatment Response and Detect Remaining Cancer in Non-Small Cell Lung Cancer — University of Miami
• Study on Whether Durvalumab and Radiation Therapy Can Slow Down Non-Small Cell Lung Cancer — Memorial Sloan Kettering Cancer Center
• DISCERN: Comparing Two Immune Therapy Combinations for PD-L1 Negative Non-Small Cell Lung Cancer — University of Alabama at Birmingham
• Study on Mavrostobart (PT199) Alone and with Other Cancer Treatments (MORNINGSTAR Study) — Phanes Therapeutics
• Study on MEDI4736 for Patients with Completely Removed Non-Small Cell Lung Cancer — Canadian Cancer Trials Group
• Study on DRP-104 for Patients with Specific Genetic Changes in Non-Small Cell Lung Cancer — NYU Langone Health
• Study on Pembrolizumab with Chemotherapy Before and After Surgery for Treatable Stage II, IIIA, and IIIB Non-Small Cell Lung Cancer — Merck Sharp & Dohme LLC
• Study on AL3818 and Nivolumab for Treating Advanced Solid Tumors — Sarcoma Oncology Research Center, LLC
• Study Comparing Ensartinib to Crizotinib in ALK Positive Non-Small Cell Lung Cancer Patients — Xcovery Holdings, Inc.
• Access Program for Neladalkib (NVL-655) for Patients with Advanced ALK+ Lung Cancer — Nuvalent Inc.
• Expanded Access Program for Zidesamtinib (NVL-520) in Patients with Advanced ROS1+ Non-Small Cell Lung Cancer — Nuvalent Inc.
• Study on FOG-001 for Advanced or Metastatic Solid Tumors — Fog Pharmaceuticals, Inc.
• Study on MPDL3280A with Chemotherapy and Radiation for Lung Cancer — M.D. Anderson Cancer Center
• Study on Neladalkib (NVL-655) for Patients with Untreated Advanced ALK-Positive Non-Small Cell Lung Cancer — Nuvalent Inc.
• Study on Nivolumab, Alone or with Ipilimumab, Before Surgery for Resectable Non-Small Cell Lung Cancer (NSCLC) — Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
• Study on Osimertinib and Gefitinib for Untreated Advanced EGFR Mutant Lung Cancer — Dana-Farber Cancer Institute
• Study on Patient Preference for Subcutaneous vs. Intravenous Immune Therapy — Diwakar Davar
• Study on Pembrolizumab and Vorinostat for Patients with Advanced Stage IV Non-Small Cell Lung Cancer — H. Lee Moffitt Cancer Center and Research Institute
• Study on Gavo-cel (TC-210) for Treating Advanced Cancers with Mesothelin Expression — TCR2 Therapeutics
• Phase 1/2 Study of S241656 for Cancers with Specific RAS/MAPK Mutations — Institut de Recherches Internationales Servier
• Study on the Safety and Effectiveness of ST-067 in Patients with Advanced Solid Tumors — Simcha IL-18, Inc.
• Phase 2 Study of Fingolimod for Lung Cancer Treatment — Medical University of South Carolina
• Phase I/II Study of Nivolumab and Ipilimumab Combined with Nintedanib for Non-Small Cell Lung Cancer — H. Lee Moffitt Cancer Center and Research Institute
• Phase II Study of New Cancer Treatments for NSCLC Patients Who Didn't Respond to Anti-PD-1/PD-L1 Therapy — AstraZeneca
• Phase III Study of Osimertinib With or Without Datopotamab Deruxtecan for Advanced Non-small Cell Lung Cancer — AstraZeneca
• Study on JDQ443 Combination Therapy for Advanced Solid Tumors with KRAS G12C Mutation — Novartis Pharmaceuticals
• Study on Combining Radiation with Tarlatamab for DLL3 Expressing Tumors — University of Arizona
• Study on Using Radiotherapy to Prevent Cancer Growth in Metastatic Non-Small-Cell Lung Cancer — Canadian Cancer Trials Group
• Study on Using Stereotactic Body Radiation Therapy (SBRT) for Patients with Metastatic Breast and Lung Cancers — Memorial Sloan Kettering Cancer Center
• Study on Reduced Chemotherapy and Immunotherapy for Older Adults with Advanced Non-Small Cell Lung Cancer — Virginia Commonwealth University
• Study on the Safety and Effectiveness of Zimberelimab, Domvanalimab, and Etrumadenant for Previously Treated Non-Small Cell Lung Cancer — Washington University School of Medicine
• Study on the Safety and Early Effectiveness of BNT327 with Chemotherapy for Advanced Non-Small Cell Lung Cancer — BioNTech SE
• Study on the Safety and Tolerability of TNG456 Alone and with Abemaciclib in Patients with Solid Tumors with MTAP Loss — Tango Therapeutics, Inc.
• Study on the Safety and Effectiveness of BNT327 with Chemotherapy for Lung Cancer — BioNTech SE
• Study on the Effectiveness and Safety of Zimberelimab and Domvanalimab for Lung Cancer — Arcus Biosciences, Inc.
• Study on DPX-Survivac with Low Dose Cyclophosphamide and Pembrolizumab for Advanced and Recurrent Solid Tumors — ImmunoVaccine Technologies, Inc. (IMV Inc.)
• Study of CP-383 for Patients with Advanced or Metastatic Solid Tumors — Tasca Therapeutics
• Study on Daraxonrasib for Previously Treated Patients with RAS Mutated Non-Small Cell Lung Cancer (NSCLC) — Revolution Medicines, Inc.
• Study Comparing DS-1062a and Docetaxel for Advanced Non-Small Cell Lung Cancer — Daiichi Sankyo
• Study on Healthy Donor FMT and Pembrolizumab for Relapsed/Refractory PD-L1 Positive Lung Cancer — Diwakar Davar
• Study Comparing Izalontamab Brengitecan with Standard Chemotherapy for EGFR-Mutated Non-Small Cell Lung Cancer After EGFR TKI Therapy Failure — Bristol-Myers Squibb
• Study Comparing JDQ443 and Docetaxel for Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer — Novartis Pharmaceuticals
• Study of Osimertinib With and Without Ramucirumab in Advanced Non-Small Cell Lung Cancer — Xiuning Le
• Study Comparing Subcutaneous and Intravenous Pembrolizumab with Chemotherapy for Advanced Non-Small Cell Lung Cancer — Merck Sharp & Dohme LLC
• Study Comparing Sacituzumab Govitecan and Docetaxel for Advanced Non-Small Cell Lung Cancer — Gilead Sciences
• Study of STK-012 Alone and With Other Treatments for Advanced Lung Cancer and Other Cancers — Synthekine
• Study on Telisotuzumab Vedotin for Previously Treated c-Met+ Non-Small Cell Lung Cancer — AbbVie
• Study on Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy for First-time Treatment of HER2 Overexpressing Non-small Cell Lung Cancer — Daiichi Sankyo
• Study on Atezolizumab Compared to Best Supportive Care After Chemotherapy in Lung Cancer Patients [IMpower010] — Hoffmann-La Roche
• Study on Firmonertinib vs. Other EGFR Inhibitors for Advanced Non-Small Cell Lung Cancer with Uncommon Mutations — ArriVent BioPharma, Inc.
• Symbiotic-Lung-10: Study on PF-08634404 Alone or with Chemotherapy for Early-stage or Locally Advanced Non-Small Cell Lung Cancer (NSCLC) — Pfizer
• Study on PF-08634404 with Other Cancer Medicines for Advanced Cancers — Pfizer
• Study on How the Combination of Sigvotatug Vedotin and Pembrolizumab Works in People with Non-Small Cell Lung Cancer with High PD-L1 Levels — Pfizer
• Study on Trabedersen (OT-101) and Pembrolizumab for Newly Diagnosed Advanced Non-Small Cell Lung Cancer with Positive PD-L1 — University of Nebraska
• Study on SPEDOX-6 for Advanced Cancers — University of California, Irvine
• Study on TT-10 and TT-4 as Single Agents and in Combination for Advanced Solid Tumors — Portage Biotech
• Study on Using High Dose Radiation Followed by Chemotherapy and Radiation for Treating Locally Advanced Non-Small Cell Lung Cancer (NSCLC) — Wake Forest University Health Sciences
• Study on VMD-928 Alone and with Pembrolizumab for Treating Solid Tumors or Lymphoma with High TrkA Levels — VM Oncology, LLC
• Study on Volrustomig with Other Cancer Drugs for Advanced Non-Small Cell Lung Cancer — AstraZeneca
• Study Comparing Zimberelimab and Domvanalimab with Chemotherapy to Pembrolizumab with Chemotherapy in Patients with Untreated Metastatic Non-Small Cell Lung Cancer — Gilead Sciences
• Study on Pembrolizumab and Berahyaluronidase Alfa for Treating Newly Diagnosed Metastatic Non-Small Cell Lung Cancer — Merck Sharp & Dohme LLC
• Study on EMB-01 Dose Escalation and Expansion for Adults with Advanced or Metastatic Solid Tumors — Shanghai EpimAb Biotherapeutics Co., Ltd.
• Global Study on Rilvegostomig or Pembrolizumab with Chemotherapy for First-Line Treatment of Metastatic Squamous Non-Small Cell Lung Cancer — AstraZeneca
• Global Study on Durvalumab and Domvanalimab After Chemoradiation for Stage III Unresectable Non-Small Cell Lung Cancer (NSCLC) — AstraZeneca
• Global Study on Durvalumab with Oleclumab or Monalizumab After Chemoradiation for Stage III Unresectable Non-Small Cell Lung Cancer — AstraZeneca
• Global Study on Osimertinib for Patients with Early-Stage EGFR-Mutated Non-Small Cell Lung Cancer After Tumor Removal — AstraZeneca
• A Phase 1/2 Study of DCC-3116 in Patients With RAS/MAPK Pathway Mutant Solid Tumors — Deciphera Pharmaceuticals, LLC
• Study on MRTX0902 for Treating Solid Tumors with KRAS MAPK Pathway Mutations — Mirati Therapeutics Inc.
• Study on CLN-081 for Patients with Non-Small Cell Lung Cancer — Cullinan Therapeutics Inc.
• Study on TC-510 Cell Therapy for Advanced Cancers with Mesothelin Expression — TCR2 Therapeutics
• Phase 2 Study of Adding Vitamin C to Chemotherapy and Radiation for Non-Small Cell Lung Cancer — Joseph J. Cullen, MD, FACS
• Study Comparing Sotorasib and Durvalumab for Non-Small Cell Lung Cancer (NSCLC) — Memorial Sloan Kettering Cancer Center
• Study on FMC-376 for Patients with KRAS G12C Mutated Advanced Solid Tumors — Frontier Medicines Corporation
• Study Comparing Divarasib with Sotorasib or Adagrasib for Treating Advanced KRAS G12C-positive Lung Cancer — Hoffmann-La Roche
• Study on the Effectiveness and Safety of Different Treatments for Stage III Non-Small Cell Lung Cancer — Hoffmann-La Roche

Looking for a program not shown above? Search the full catalog for “Non-Small-Cell Lung Cancer” to see every match including additional filters.